Thank you, Madam Chair.
Thank you, Dr. Dal Pan, for your presentation this morning and for being with us to answer our questions.
I want to go back for a moment, please, to the life-cycle approach. I think you said that in the United States--and it's true in Canada too--you balance the benefit and the risk of a drug before it's licensed, and that's some of the determination that goes into it. You also said, I think, that you learn about the drug during its life cycle.
I'm sure you're aware that there's legislation before our Parliament to introduce a life-cycle approach to the regulation of these products. Health Canada has said much the same thing. They indicate that the concept of this life-cycle approach is that over time there's a progression of knowledge in and about the drug.
Could you outline the difference between what you do and what we're proposing here with this new legislation?